

PRODUCT MONOGRAPH  
INCLUDING PATIENT MEDICATION INFORMATION

 **TARO-AMPHETAMINE XR**

mixed salts amphetamine

extended-release capsule

5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg

(as d-amphetamine Saccharate, Amphetamine Aspartate Monohydrate, d-amphetamine Sulfate,  
Amphetamine Sulfate)

For oral use

Central Nervous System Stimulant

Sun Pharma Canada Inc.  
126 East Drive,  
Brampton, Ontario  
Canada L6T1C1

Date of Initial Authorization:  
MAR 18, 2021

Date of Revision:  
FEB 09, 2026

Submission Control Number: 303569

**RECENT MAJOR LABEL CHANGES**

<a href="#">2 CONTRAINDICATIONS</a>	03/2025
<a href="#">7 WARNINGS AND PRECAUTIONS, Cardiovascular, QTc Prolongation</a>	03/2025

**TABLE OF CONTENTS**

Certain sections or subsections that are not applicable at the time of the preparation of the most recent authorized product monograph are not listed.

**RECENT MAJOR LABEL CHANGES ..... 2**

**TABLE OF CONTENTS ..... 2**

**PART I: HEALTHCARE PROFESSIONAL INFORMATION ..... 4**

**1 INDICATIONS..... 4**

    1.1 Pediatrics ..... 4

    1.2 Geriatrics ..... 4

**2 CONTRAINDICATIONS..... 4**

**3 SERIOUS WARNINGS AND PRECAUTIONS BOX ..... 5**

**4 DOSAGE AND ADMINISTRATION ..... 5**

    4.1 Dosing Considerations..... 5

    4.2 Recommended Dose and Dosage Adjustment ..... 6

    4.4 Administration ..... 6

    4.5 Missed Dose ..... 6

**5 OVERDOSAGE..... 7**

**6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING..... 8**

**7 WARNINGS AND PRECAUTIONS ..... 9**

    General ..... 9

    Carcinogenesis and Genotoxicity..... 9

    Cardiovascular ..... 9

    Dependence, Tolerance and/or Abuse Liability..... 11

    Endocrine and Metabolism ..... 11

    Neurologic ..... 11

    Ophthalmologic..... 12

    Psychiatric ..... 12

    Renal ..... 13

    Reproductive Health ..... 13

**7.1 Special Populations..... 13**

        7.1.1 Pregnancy ..... 13

        7.1.2 Breastfeeding..... 14

7.1.3 Pediatrics .....	14
7.1.4 Geriatrics.....	14
<b>8 ADVERSE REACTIONS .....</b>	<b>14</b>
8.1 Adverse Reaction Overview.....	14
8.2 Clinical Trial Adverse Reactions .....	15
8.2.1 Clinical Trial Adverse Reactions - Pediatrics .....	17
8.3 Less Common Clinical Trial Adverse Reactions .....	20
8.5 Post-Market Adverse Reactions .....	20
<b>9 DRUG INTERACTIONS .....</b>	<b>21</b>
9.1 Serious Drug Interactions.....	21
9.2 Drug Interactions Overview .....	21
9.4 Drug-Drug Interactions .....	21
9.5 Drug-Food Interactions .....	22
9.6 Drug-Herb Interactions .....	22
9.7 Drug-Laboratory Test Interactions.....	23
<b>10 CLINICAL PHARMACOLOGY.....</b>	<b>23</b>
10.1 Mechanism of Action .....	23
10.2 Pharmacodynamics.....	23
10.3 Pharmacokinetics.....	24
<b>11 STORAGE, STABILITY AND DISPOSAL.....</b>	<b>28</b>
<b>PART II: SCIENTIFIC INFORMATION.....</b>	<b>29</b>
<b>13 PHARMACEUTICAL INFORMATION .....</b>	<b>29</b>
<b>14 CLINICAL TRIALS .....</b>	<b>30</b>
14.1 Clinical Trials by Indication .....	30
14.2 Comparative Bioavailability Studies .....	32
14.3 Comparative Bioavailability Studies .....	33
<b>16 NON-CLINICAL TOXICOLOGY .....</b>	<b>36</b>
<b>17 Supporting Product Monographs .....</b>	<b>37</b>
<b>PATIENT MEDICATION INFORMATION.....</b>	<b>38</b>

## PART I: HEALTHCARE PROFESSIONAL INFORMATION

### 1 INDICATIONS

TARO-AMPHETAMINE XR (mixed salts amphetamine extended-release capsules) is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in:

- **Children (6 – 12 years of age)**
- **Adolescents (13 – 17 years of age)**
- **Adults (18 years of age or older)**

#### Need for Comprehensive Treatment Program

TARO-AMPHETAMINE XR is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, social) for patients with this syndrome. Drug treatment may not be indicated for all patients with this syndrome. Drug treatment is not intended for use in the patient who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis. Appropriate educational placement is essential in patients with this diagnosis and psychosocial intervention is often helpful. When remedial measures alone are insufficient, the decision to prescribe drug treatment will depend upon the physician's assessment of the chronicity and severity of the patient's symptoms.

#### Long-Term Use

The effectiveness of mixed salts amphetamine extended-release capsules for long-term use, i.e., for more than 3 weeks in children aged 6 to 12 years and 4 weeks in adolescents aged 13 to 17 years, and adults, has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use TARO-AMPHETAMINE XR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see [4 DOSAGE AND ADMINISTRATION](#)).

#### 1.1 Pediatrics

Pediatrics (<6 years old): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for children under the age of 6 years. Amphetamines are not recommended in pediatric patients with ADHD under six years of age.

#### 1.2 Geriatrics

Mixed salts amphetamine extended-release capsules has not been systematically studied in the geriatric population. In general, dose selection for an elderly patient should start at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

## 2 CONTRAINDICATIONS

TARO-AMPHETAMINE XR (mixed salts amphetamine extended-release capsules) is contraindicated in patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. For a complete listing, see [6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING](#).

TARO-AMPHETAMINE XR is contraindicated in patients with the following conditions:

- Advanced arteriosclerosis

- Symptomatic cardiovascular disease
- Moderate to severe hypertension
- Hyperthyroidism
- Known hypersensitivity or idiosyncrasy to the sympathomimetic amines
- Glaucoma
- Agitated states
- History of drug abuse
- Pheochromocytoma
- During or within 14 days following the administration of monoamine oxidase inhibitors (hypertensive crises may result; see [7 WARNINGS AND PRECAUTIONS](#); [9.4 Drug-Drug Interactions](#))
- Allergy to amphetamines

### 3 SERIOUS WARNINGS AND PRECAUTIONS BOX

#### Serious Warnings and Precautions

##### Misuse and Serious Cardiovascular Adverse Events

Amphetamines have a potential for abuse, misuse, dependence, or diversion for non-therapeutic uses that physicians should consider when prescribing this product ([see 7 WARNINGS AND PRECAUTIONS, Dependence, Tolerance, and/or Abuse Liability](#)).

The misuse of amphetamines may cause serious cardiovascular adverse events and sudden death.

### 4 DOSAGE AND ADMINISTRATION

#### 4.1 Dosing Considerations

- TARO-AMPHETAMINE XR is a once-a-day capsule administered orally in the morning. TARO-AMPHETAMINE XR dosage should be individualized according to the needs and response of the patient.
- TARO-AMPHETAMINE XR should be administered starting at the lowest possible dose. Dosage should then be individually and slowly adjusted, to the lowest effective dosage, since individual patient response to TARO-AMPHETAMINE XR varies widely.
- In patients with severe renal insufficiency (GFR 15 to <30 mL/min/1.73 m<sup>2</sup>), the maximum dose should not exceed 20 mg/day. Further dosage reduction should be considered in patients undergoing dialysis (see [10.3 Pharmacokinetics, Special Populations and Conditions](#); [7 WARNINGS AND PRECAUTIONS, Renal](#)).
- Prior to the initiation of treatment with sympathomimetic medications, a personal and family history (including assessment for a family history of sudden death or ventricular arrhythmia) and physical exam should be obtained to assess for the presence of cardiac disease. In patients with relevant risk factors and based on the clinician's judgment, further cardiovascular evaluation may be considered (e.g., electrocardiogram and echocardiogram) (see [7 WARNINGS AND PRECAUTIONS, Cardiovascular](#)). Patients who develop symptoms such as exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease during ADHD treatment should undergo a prompt cardiac

evaluation.

- Patients who are considered to need extended treatment with TARO-AMPHETAMINE XR should undergo periodic evaluation of their cardiovascular status (see [7 WARNINGS AND PRECAUTIONS, Cardiovascular](#)).
- Careful clinical evaluation for motor or verbal tics of Tourette's syndrome should be conducted before initiating TARO-AMPHETAMINE XR (see 7 WARNINGS AND PRECAUTIONS, Neurologic, Tics).
- Prior to initiating TARO-AMPHETAMINE XR treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, and depression) (see 7 WARNINGS AND PRECAUTIONS, Psychiatric, Screening Patients for Bipolar Disorder).

## 4.2 Recommended Dose and Dosage Adjustment

### Children (6 to 12 years of age)

**Amphetamines are not recommended for children under 6 years of age.** When in the judgment of the clinician a lower dose is appropriate, patients may begin treatment with 5 mg once daily in the morning. The usual starting dose is 10 mg daily. The daily dosage may be adjusted in increments of 5 mg to 10 mg at weekly intervals, as determined by clinical response and tolerability up to the maximum recommended dose of 30 mg per day.

### Adolescents (13 to 17 years of age) and Adults (over 18 years of age)

In adolescents and adults with ADHD who are either starting treatment for the first time or switching from another stimulant medication, start with 10 mg once daily in the morning; daily dosage may be adjusted in increments of 5 to 10 mg at weekly intervals up to a usual maximum of 20 mg. In some cases, higher doses not to exceed 30 mg/day may be required, as determined by clinical response and tolerability.

## 4.4 Administration

TARO-AMPHETAMINE XR is a once-a-day capsule for the treatment of ADHD containing immediate-release and delayed-release pellets. Capsules may be taken whole with water in the morning, or the capsule may be opened and the entire contents sprinkled on applesauce. If using the sprinkle administration method, the sprinkled applesauce should be consumed immediately and not stored. Patients should eat the applesauce with sprinkled beads in its entirety and refrain from chewing.

The dose of a single capsule should not be divided-the contents of the entire capsule should be taken.

Afternoon doses should be avoided because of the long-acting nature of the drug, including the potential for insomnia.

Where possible, drug administration should be interrupted occasionally to determine if there is a recurrence of behavioral symptoms sufficient to require continued therapy.

## 4.5 Missed Dose

If a dose is missed in the morning, wait until the next morning and carry on with the next dose at the usual time. Do not double dose.

## 5 OVERDOSAGE

Individual patient response to amphetamines varies widely. Toxic symptoms may occur idiosyncratically at low doses.

**Symptoms:** Manifestations of acute overdose with amphetamines include restlessness, tremor, hyperreflexia, rapid respiration, confusion, assaultiveness, hallucinations, panic states, hyperpyrexia and rhabdomyolysis. Fatigue and depression usually follow the central nervous system stimulation. Cardiovascular effects include arrhythmias, hypertension or hypotension and circulatory collapse. Takotsubo cardiomyopathy may develop. Gastrointestinal symptoms include nausea, vomiting, diarrhea, and abdominal cramps. Fatal poisoning is usually preceded by convulsions and coma.

Posterior reversible encephalopathy syndrome (PRES) has been reported in association with amphetamine overdose. Symptoms indicating PRES include headache, altered mental status, seizures and visual disturbances. Diagnosis should be confirmed by radiological procedure (e.g., MRI). If PRES is suspected or diagnosed, appropriate measures should be taken. Symptoms of PRES are usually reversible but may evolve into ischemic stroke or cerebral hemorrhage. Delay in diagnosis and treatment may lead to permanent neurological sequelae.

**Treatment:** Treatment of overdose consists of appropriate supportive measures. Consult with a Certified Poison Control Center for up to date guidance and advice. Management of acute amphetamine intoxication is largely symptomatic and includes administration of activated charcoal, administration of a cathartic and sedation. Experience with hemodialysis or peritoneal dialysis is inadequate to permit its recommendation in this regard. *D*-amphetamine is not dialyzable. Acidification of the urine increases amphetamine excretion, but is believed to increase risk of acute renal failure if myoglobinuria is present. If acute severe hypertension complicates amphetamine overdose, administration of intravenous phentolamine has been suggested. However, a gradual drop in blood pressure will usually result when sufficient sedation has been achieved. Chlorpromazine antagonizes the central stimulant effects of amphetamines and can be used to treat amphetamine intoxication.

The prolonged release of mixed salts amphetamine from TARO-AMPHETAMINE XR (mixed salts amphetamine extended-release capsules) should be considered when treating patients with overdose.

### Animal Toxicology

Acute administration of high doses of amphetamine (*d*- or *d,l*-) has been shown to produce long-lasting neurotoxic effects, including irreversible nerve fiber damage, in rodents. The significance of these findings to humans is unknown.

For the most recent information in the management of a suspected drug overdose, contact your regional poison control centre or Health Canada's toll-free number, 1-844 POISON-X (1-844-764-7669).
---

## 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING

<b>Route of Administration</b>	<b>Dosage Form / Strength/Composition</b>	<b>Non-medicinal Ingredients</b>
Oral	Capsule 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg	The inactive ingredients in TARO-AMPHETAMINE XR capsules include: black iron oxide, colloidal silicon dioxide, FD&C Blue #2 (5 mg, 10 mg and 15 mg), FD&C Yellow #6, gelatin, hypromellose, methacrylic acid copolymer Type-B, methacrylic acid copolymer Type-C, polyethylene glycol, propylene glycol, shellac, sugar spheres, talc, titanium dioxide and triethyl citrate. The 20 mg, 25 mg, and 30 mg capsules also contains yellow iron oxide and red iron oxide-

TARO-AMPHETAMINE XR is a long-acting, modified-release, single-entity amphetamine product designed for once-daily administration combining the neutral sulfate salts of d-amphetamine and amphetamine, with the d-isomer of amphetamine saccharate and *d,l* amphetamine aspartate. The TARO-AMPHETAMINE XR capsule contains two types of drug-containing beads designed to give a double-pulsed delivery of amphetamines, which provides for its prolonged duration of action.

**Table 2 – Amphetamine Quantities in TARO-AMPHETAMINE XR Capsules**

	<u>5 mg</u>	<u>10 mg</u>	<u>15 mg</u>	<u>20 mg</u>	<u>25 mg</u>	<u>30 mg</u>
<i>d</i> -amphetamine Saccharate (mg)	1.25	2.5	3.75	5.0	6.25	7.5
Amphetamine Aspartate Monohydrate (mg)	1.25	2.5	3.75	5.0	6.25	7.5
<i>d</i> -amphetamine Sulfate USP (mg)	1.25	2.5	3.75	5.0	6.25	7.5
Amphetamine Sulfate USP (mg)	1.25	2.5	3.75	5.0	6.25	7.5
Total racemic amphetamine base equivalence (mg)	1.5	3.0	4.5	6.0	7.5	9.0
Total non-racemic <i>d</i> -amphetamine base equivalence (mg)	1.6	3.3	4.9	6.5	8.1	9.8

TARO-AMPHETAMINE XR 5 mg Capsules: Size “3” Hard gelatin capsule, light blue colored opaque cap and natural transparent body imprinted with ‘336’ on cap and ‘5 mg’ on body in black ink containing light orange colored pellets. Bottles of 100.

TARO-AMPHETAMINE XR 10 mg Capsules: Size “3” Hard gelatin capsule, powder blue colored opaque cap and body imprinted with ‘337’ on cap and ‘10 mg’ on body in black ink containing light orange colored pellets. Bottles of 100.

TARO-AMPHETAMINE XR 15 mg Capsules: Size “2” Hard gelatin capsule, white colored opaque cap and powder blue transparent body imprinted with ‘338’ on cap and ‘15 mg’ on body in black ink containing light orange colored pellets. Bottles of 100.

TARO-AMPHETAMINE XR 20 mg Capsules: Size “2” Hard gelatin capsule, medium orange opaque colored cap and body imprinted with ‘339’ on cap and ‘20 mg’ on body in black ink containing light orange colored pellets. Bottles of 100.

TARO-AMPHETAMINE XR 25 mg Capsules: Size “1” Hard gelatin capsule, white colored opaque cap and medium orange colored opaque body imprinted with ‘340’ on cap and ‘25 mg’ on body in black ink containing light orange colored pellets. Bottles of 100.

TARO-AMPHETAMINE XR 30 mg Capsules: Size “1” Hard gelatin capsule, medium orange colored opaque cap and natural transparent body imprinted with ‘341’ on cap and ‘30 mg’ on body in black ink containing light orange colored pellets. Bottles of 100.

## 7 WARNINGS AND PRECAUTIONS

Please see [3 SERIOUS WARNINGS AND PRECAUTIONS BOX](#).

### General

The least amount of amphetamine feasible should be prescribed or dispensed at one time in order to minimize the possibility of overdose. TARO-AMPHETAMINE XR (mixed salts amphetamine extended-release capsules) should be used with caution in patients who use other sympathomimetic drugs.

### Carcinogenesis and Genotoxicity

No evidence of carcinogenicity was found in studies in which *d,l*-amphetamine (enantiomer ratio of 1:1) was administered to mice and rats in the diet for 2 years at doses of up to 30 mg/kg/day in male mice, 19 mg/kg/day in female mice, and 5 mg/kg/day in male and female rats. These doses are approximately 2.4, 1.5, and 0.8 times, respectively, the maximum recommended human dose of 30 mg/day on a mg/m<sup>2</sup> body surface area basis.

Amphetamine, in the enantiomer ratio present in mixed salts amphetamine extended-release capsules (*d*- to *l*- ratio of 3:1), was not clastogenic in the mouse bone marrow micronucleus test in vivo and was negative when tested in the *E. coli* component of the Ames test in vitro. *d,l*-amphetamine (1:1 enantiomer ratio) has been reported to produce a positive response in the mouse bone marrow micronucleus test, an equivocal response in the Ames test, and negative responses in the in vitro sister chromatid exchange and chromosomal aberration assays.

### Cardiovascular

#### *Pre-existing Structural Cardiac Abnormalities or Other Serious Heart Problems and Sudden Death*

Children/Adolescents: Sudden death has been reported with sympathomimetic drugs used for ADHD treatment at therapeutic doses in children/adolescents with structural cardiac abnormalities or other serious heart problems. Although some serious heart problems alone carry an increased risk of sudden death, TARO-AMPHETAMINE XR (mixed salts amphetamine extended-release capsules) generally should not be used in children/adolescents with known serious structural cardiac abnormalities or other serious heart problems (e.g., cardiomyopathy, serious heart rhythm abnormalities) that may place them at increased vulnerability to the sympathomimetic effects of ADHD

drugs (see [2 CONTRAINDICATIONS](#)).

Adults: Sudden deaths, stroke, and myocardial infarction have been reported in adults taking stimulant drugs at usual doses for ADHD. Although the role of stimulants in these adult cases is also unknown, adults have a greater likelihood than children of having serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems. Adults with such abnormalities should also generally not be treated with stimulant drugs (see [2 CONTRAINDICATIONS](#)).

Children: Theoretically there exists a pharmacological potential for all ADHD drugs to increase the risk of sudden/cardiac death. Although confirmation of an incremental risk for adverse cardiac events arising from treatment with ADHD medications is lacking, prescribers should consider this potential risk.

#### *Hypertension and other Cardiovascular Conditions*

Sympathomimetic medications can cause a modest increase in average blood pressure and average heart rate and individuals may have larger increases. While the mean changes alone would not be expected to have short-term consequences, all patients should be monitored for larger changes in heart rate and blood pressure. Caution is indicated in treating patients whose underlying medical conditions might be compromised by increases in blood pressure or heart rate, e.g., those with pre-existing hypertension, heart failure, recent myocardial infarction, or ventricular arrhythmia (see [2 CONTRAINDICATIONS](#)). Blood pressure and pulse should be monitored at appropriate intervals in patients taking TARO-AMPHETAMINE XR, especially patients with hypertension.

All drugs with sympathomimetic effects prescribed in the management of ADHD should be used with caution in patients who: a) are involved in strenuous exercise or activities b) use other sympathomimetic drugs or c) have a family history of sudden/cardiac death. Prior to the initiation of treatment with sympathomimetic medications, a personal and family history (including assessment for a family history of sudden death or ventricular arrhythmia) and physical exam should be obtained to assess for the presence of cardiac disease. In patients with relevant risk factors and based on the clinician's judgment, further cardiovascular evaluation may be considered (e.g., electrocardiogram and echocardiogram). Patients who develop symptoms such as exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease during ADHD treatment should undergo a prompt cardiac evaluation.

#### *QTc Prolongation*

TARO-AMPHETAMINE XR has been shown to prolong QTc interval in some patients (see [8.5 Post-Market Adverse Reactions](#)). It should be used with caution in patients with known prolongation of the QTc interval or congenital Long QT syndrome, in patients treated with drugs affecting the QTc interval or in patients with relevant pre-existing cardiac disease or electrolyte disturbances.

TARO-AMPHETAMINE XR is contraindicated in patients with symptomatic cardiovascular disease and also in patients with moderate to severe hypertension (see [2 CONTRAINDICATIONS](#)).

#### *Peripheral Vasculopathy, Including Raynaud's Phenomenon*

Stimulants, such as TARO-AMPHETAMINE XR, are associated with peripheral vasculopathy, including Raynaud's phenomenon. Signs and symptoms are usually intermittent and mild; however, very rare sequelae include digital ulceration and/or soft tissue breakdown. Although rare, a number of instances of a condition resembling Raynaud's phenomenon have been reported in clinical trials. Effects of peripheral

vasculopathy, including Raynaud's phenomenon, were observed in post-marketing reports at different times and at therapeutic doses in all age groups throughout the course of treatment. Signs and symptoms generally improve after reduction in dose or discontinuation of drug. Careful observation for digital changes is necessary during treatment with stimulants. Further clinical evaluation (e.g., rheumatology referral) may be appropriate for certain patients. Caution should therefore be observed if patients with Raynaud's disease or thromboangiitis obliterans (Buerger's disease) are to be treated with TARO-AMPHETAMINE XR.

### **Dependence, Tolerance and/or Abuse Liability**

Amphetamines have been extensively abused (see [3 SERIOUS WARNINGS AND PRECAUTIONS BOX](#)). Tolerance, extreme psychological dependence, and severe social disability have occurred. There are reports of patients who have increased the dosage to levels many times higher than recommended. The smallest possible amount of the drug should be prescribed or dispensed at one time. The possibility of tolerance and psychological dependence, particularly with excessive use, should be kept in mind. Therefore, care should be taken in the selection of patients for amphetamine extended-release capsules therapy, in particular if patients have a previous history of drug or alcohol abuse/dependence. Abrupt cessation following prolonged high dosage administration results in extreme fatigue and mental depression; changes are also noted on the sleep EEG. Careful supervision is therefore recommended during drug withdrawal. Manifestations of chronic intoxication with amphetamines may include severe dermatoses, marked insomnia, irritability, hyperactivity, and personality changes. The most severe manifestation of chronic intoxication is psychosis, often clinically indistinguishable from schizophrenia.

### **Endocrine and Metabolism**

#### *Long-Term Suppression of Growth*

In a controlled trial of mixed salts amphetamine extended-release capsules in adolescents aged 13 to 17 years, mean weight change from baseline within the initial 4 weeks of therapy was -1.1 lbs and -2.8 lbs, respectively, for patients receiving 10 mg and 20 mg mixed salts amphetamine extended-release capsules. Higher doses were associated with greater weight loss within the initial 4 weeks of treatment.

Published data for other stimulants report that in children aged 7-10 years, there is a temporary slowing in growth rate without evidence of growth rebound on treatment. Data are inadequate to determine whether the chronic use of amphetamines, in children may be causally associated with suppression of growth. Therefore, growth should be monitored during treatment, and patients who are not growing or gaining weight as expected may need to have their treatment interrupted.

### **Neurologic**

#### *Tics*

Amphetamines have been reported to exacerbate motor and phonic tics in Tourette's syndrome. Therefore, careful clinical evaluation for tics in Tourette's syndrome in children and their families should precede use of stimulant medications. Mixed salts amphetamine extended-release capsules have been associated with new onset of tics (not necessarily associated with Tourette's syndrome).

#### *Seizures*

There is some clinical evidence that stimulants may lower the convulsive threshold in patients with prior history of seizures, in patients with prior EEG abnormalities in absence of seizures, and, very rarely, in patients without a history of seizures and no prior EEG evidence of seizures. In the presence of seizures, the drug should be discontinued.

#### *Serotonin toxicity/Serotonin syndrome*

Serotonin toxicity also known as serotonin syndrome is a potentially life-threatening condition and has been reported with amphetamines, including TARO-AMPHETAMINE XR, particularly during combined use with other serotonergic drugs, such as selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Other common serotonergic drugs include: tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs), serotonin 5-HT<sub>1</sub> receptor agonists (triptans), and 5-HT<sub>3</sub> receptor antagonist antiemetics (See [9.4 Drug-Drug Interactions](#)).

Serotonin toxicity is characterised by neuromuscular excitation, autonomic stimulation (e.g. tachycardia, flushing) and altered mental state (e.g. anxiety, agitation, hypomania). In accordance with the Hunter Criteria, serotonin toxicity diagnosis is likely when, in the presence of at least one serotonergic agent, one of the following is observed:

- Spontaneous clonus
- Inducible clonus or ocular clonus with agitation or diaphoresis
- Tremor and hyperreflexia
- Hypertonia and body temperature >38°C and ocular clonus or inducible clonus.

If concomitant treatment with TARO-AMPHETAMINE XR and other serotonergic agents is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see [9.4 Drug-Drug Interactions](#)). If serotonin toxicity is suspected, discontinuation of the serotonergic agents should be considered.

### **Ophthalmologic**

Difficulties with accommodation and blurring of vision have been reported with stimulant treatment (see [2 CONTRAINDICATIONS](#)).

### **Psychiatric**

#### *Pre-existing Psychosis*

Administration of stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a pre-existing psychotic disorder.

#### *Screening Patients for Bipolar Disorder*

Particular care should be taken in using stimulants to treat ADHD in patients with comorbid bipolar disorder because of concern for possible induction of a mixed/manic episode in such patients. Prior to initiating treatment with a stimulant, patients with comorbid depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression.

#### *Emergence of New Psychotic or Manic Symptoms*

Treatment emergent psychotic or manic symptoms, e.g., hallucinations, delusional thinking, or mania in children / adolescents without a prior history of psychotic illness or mania can be caused by stimulants at usual doses. If such symptoms occur, consideration should be given to a possible causal role of the stimulant, and discontinuation of treatment may be appropriate. In a pooled analysis of multiple short term, placebo-controlled studies, such symptoms occurred in about 0.1% (4 patients with events out of 3482 exposed to methylphenidate or amphetamine for several weeks at usual doses) of stimulant treated patients compared to 0 in placebo-treated patients.

#### *Aggression*

Aggressive behavior or hostility is often observed in children and adolescents with ADHD, and has been

reported in clinical trials and the postmarketing experience of some medications indicated for the treatment of ADHD. Although there is no systematic evidence that stimulants cause aggressive behavior or hostility, patients beginning treatment for ADHD should be monitored for the appearance of or worsening of aggressive behavior or hostility.

#### *Suicidal Behavior and Ideation*

There have been post-marketing reports of suicide-related events in patients treated with ADHD drugs, including cases of ideation, attempts, and very rarely, completed suicide. The mechanism of this risk is not known. ADHD and its related co-morbidities may be associated with increased risk of suicidal ideation and/or behavior. Therefore, it is recommended for patients treated with ADHD drugs that caregivers and physicians monitor for signs of suicide-related behavior, including at dose initiation/optimization and drug discontinuation. Patients should be encouraged to report any distressing thoughts or feelings at any time to their healthcare professional. Patients with emergent suicidal ideation and behavior should be evaluated immediately. The physician should initiate appropriate treatment of the underlying psychiatric condition and consider a possible change in the ADHD treatment regimen.

#### **Renal**

Due to reduced clearance of *d*-amphetamine in patients with severe renal insufficiency (GFR 15 to <30 mL/min/1.73 m<sup>2</sup>), observed in a study with lisdexamfetamine, the maximum dose of mixed salts amphetamine extended-release capsules should not exceed 20 mg/day. Further dosage reduction should be considered in patients undergoing dialysis, as *d*-amphetamine is not dialyzable. (see [10.3 Pharmacokinetics, Special Populations and Conditions](#); [4 DOSAGE AND ADMINISTRATION](#)).

#### **Reproductive Health**

- **Fertility**

Amphetamine, in the enantiomer ratio present in mixed salts amphetamine extended-release capsules (*d*- to *l*- ratio of 3:1), did not adversely affect fertility or early embryonic development in the rat at doses of up to 20 mg/kg/day (approximately 5 times the maximum recommended human dose of 30 mg/day on a mg/m<sup>2</sup> body surface area basis). See [16 NON-CLINICAL TOXICOLOGY, Reproductive and Developmental Toxicology](#).

For information on teratogenic and non-teratogenic effects, please see [7.1.1 Pregnancy](#).

### **7.1 Special Populations**

#### **7.1.1 Pregnancy**

Infants born to mothers dependent on amphetamines have an increased risk of premature delivery and low birth weight. Also, these infants may experience symptoms of withdrawal as demonstrated by dysphoria, including agitation, and significant lassitude.

Amphetamines should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

There are no adequate and well-controlled studies with mixed salts amphetamine extended-release capsules in pregnant women. There has been one report of severe congenital bony deformity, tracheoesophageal fistula, and anal atresia (VATER association) in a baby born to a woman who took *d*-amphetamine sulfate with lovastatin during the first trimester of pregnancy.

- **Teratogenic and Non-teratogenic Risks**

Amphetamine, in the enantiomer ratio present in TARO-AMPHETAMINE XR (d- to l- ratio of 3:1), had no apparent effect on embryofetal morphological development or survival when orally administered to pregnant rats and rabbits throughout the period of organogenesis at doses up to 6 and 16 mg/kg/day, respectively. These doses are approximately 1.5 and 8 times the maximum recommended human dose of 30 mg/day on a mg/m<sup>2</sup> body surface area basis. Fetal malformations and death have been reported in mice following parenteral administration of d-amphetamine doses of 50 mg/kg/day (approximately 6 times the maximum recommended human dose of 30 mg/day on a mg/m<sup>2</sup> basis) or greater to pregnant animals. Administration of these doses was also associated with severe maternal toxicity.

A number of studies in rodents indicate that prenatal or early postnatal exposure to amphetamine (d- or d,l-), at doses similar to those used clinically in children, can result in longterm neurochemical and behavioral alterations. Reported behavioral effects include learning and memory deficits, altered locomotor activity, and changes in sexual function. See [16 NON-CLINICAL TOXICOLOGY, Reproductive and Developmental Toxicology](#).

### 7.1.2 Breastfeeding

Amphetamines are excreted in human milk. Mothers taking amphetamines should be advised to refrain from nursing.

### 7.1.3 Pediatrics

**Pediatrics (6 to 17 years old):** TARO-AMPHETAMINE XR is indicated for use in children 6 years of age and older. The long-term effects of amphetamines in children have not been well established.

**Pediatrics (≤ 6 years of age):** No data are available to Health Canada; therefore, Health Canada has not authorized an indication for use in children younger than 6 years of age. Amphetamines are not recommended for use in children with ADHD under 6 years of age.

Chronic administration of amphetamines may be associated with growth inhibition; growth should be monitored during treatment (see [7 Warnings and Precautions, Endocrine and Metabolism](#)).

Clinical experience suggests that in psychotic children, administration of amphetamines may exacerbate symptoms of behavior disturbance and thought disorder (see [7 Warnings and Precautions, Psychiatric](#)).

The presence of tics or Tourette's syndrome should be ruled out before administering amphetamines to children (see [7 Warnings and Precautions, Neurologic](#)).

### 7.1.4 Geriatrics

Mixed salts amphetamine extended-release capsules have not been studied in the geriatric population. In general, dose selection for an elderly patient should start at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

## 8 ADVERSE REACTIONS

### 8.1 Adverse Reaction Overview

The pre-marketing development program for mixed salts amphetamine extended-release capsules included exposures in a total of 1315 participants in clinical trials (635 pediatric patients aged 6 to 12

years, 350 adolescent patients aged 13-17 years, 248 adult patients, 82 healthy adult subjects). The 635 pediatric patients were evaluated in two controlled clinical studies, one open-label clinical study, and two single-dose clinical pharmacology studies (n=40). The 248 adult patients were evaluated in one controlled clinical study and one open-label clinical study. The 350 adolescent patients were evaluated in one controlled clinical study and one pharmacokinetic study. Safety data on all patients are included in the discussion that follows. Adverse reactions were assessed by collecting adverse events, results of physical examinations, vital signs, weights, laboratory analyses, and ECGs.

In a single-dose pharmacokinetic study in 23 adolescents aged 13 to 17 years, isolated increases in systolic blood pressure (above the upper 95% CI for age, gender and stature) were observed in 2/17 (12%) and 8/23 (35%), subjects administered 10 mg and 20 mg mixed salts amphetamine extended-release capsules, respectively. Higher single doses were associated with a greater increase in systolic blood pressure. All increases were transient, appeared maximal at 2 to 4 hours post dose and not associated with symptoms.

## 8.2 Clinical Trial Adverse Reactions

Clinical trials are conducted under very specific conditions. The adverse reaction rates observed in the clinical trials; therefore, may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse reaction information from clinical trials may be useful in identifying and approximating rates of adverse drug reactions in real-world use.

### Adverse Events Occurring in a Controlled Trial

Adverse events reported in a controlled fixed dose clinical study of adult patients treated with mixed salts amphetamine extended-release capsules at doses up to 60 mg/day, or placebo, for up to 4 weeks are presented in the following table.

	<b>Mixed Salts Amphetamine Extended-Release Capsules (n=191) (%)</b>	<b>Placebo (n=64) (%)</b>
<b>General</b>		
Headache	26	13
Asthenia	6	5
Pain	5	5 <sup>a</sup>
Infection	4	2
Photosensitivity Reaction	3	0
Chills	2	0
Fungal Infection	2	0
Neck Pain	2	0

**Table 3: Adverse Events Reported by ≥1% or More of Adults Receiving Fixed Doses of mixed salts amphetamine extended-release capsules (up to final doses of 20, 40 or 60 mg/day) with an Incidence Greater than Placebo in a Controlled Clinical Trial**

	Mixed Salts Amphetamine Extended-Release Capsules (n=191) (%)	Placebo (n=64) (%)
<b>Digestive System</b>		
Dry Mouth	35	5
Loss of Appetite	33	3
Nausea	8	3
Diarrhea	6	0
Constipation	4	0
Tooth Disorder	3	2
Gastroenteritis	1	0
Thirst	1	0
Vomiting	1	0
<b>Nervous System</b>		
Insomnia	27	13
Nervousness	13	13 <sup>a</sup>
Agitation	8	5
Anxiety	8	5
Dizziness	7	0
Hyperkinesia	4	3
Libido Decreased	4	0
Emotional Lability	3	2
Somnolence	3	2
Speech Disorder	2	0
Amnesia	1	0
Depersonalization	1	0
Libido Increased	1	0
<b>Cardiovascular System</b>		
Tachycardia	6	3
Palpitation	4	0
Hypertension	2	0
Vasodilation	1	0
<b>Metabolic/Nutritional</b>		
Weight Loss	10	0
Bilirubinemia	1	0
SGOT Increased	1	0
SGPT Increased	1	0
<b>Musculoskeletal</b>		
Twitching	3	0
Myalgia	2	2 <sup>a</sup>
Arthralgia	1	0
<b>Respiratory</b>		
Dyspnea	3	0
Cough Increased	1	0
Sinusitis	1	0

**Table 3: Adverse Events Reported by ≥1% or More of Adults Receiving Fixed Doses of mixed salts amphetamine extended-release capsules (up to final doses of 20, 40 or 60 mg/day) with an Incidence Greater than Placebo in a Controlled Clinical Trial**

	Mixed Salts Amphetamine Extended-Release Capsules (n=191) (%)	Placebo (n=64) (%)
<b>Skin and Appendages</b>		
Sweating	3	0
Rash	2	0
<b>Special Senses</b>		
Taste Perversion	2	0
<b>Urogenital System</b>		
Urinary Tract Infection	5	0
Dysmenorrhea	2	0
Impotence	2	0
Oliguria	1	0
Urinary Tract Disorder	1	0
Urination Impaired	1	0

<sup>a</sup> Appears the same due to rounding

### Adverse Events Associated with Discontinuation of Treatment

In one placebo-controlled, 4-week study in adults with ADHD, the most frequent adverse events resulting in discontinuation (>0.5%) in mixed salts amphetamine extended-release capsules treated patients (n=191) were for nervousness including anxiety and irritability (3.1%); for insomnia (2.6%); and for headache, palpitation, and somnolence (1% each). In an open-label extension of the trial (n=223), at 12 months, the only adverse event leading to discontinuation that was reported by at least 2% of patients was depression (4.9%).

Adverse events leading to discontinuations for mixed salts amphetamine extended-release capsules trials in adults were consistent with those reported in mixed salts amphetamine extended-release capsules trials in children (see [8.2.1 Clinical Trial Adverse Reactions – Pediatrics](#)) and were also consistent with the known side effects for amphetamines.

### 8.2.1 Clinical Trial Adverse Reactions - Pediatrics

#### Adverse Events Occurring in a Controlled Trial

Adverse events reported in a controlled fixed-dose clinical study of pediatric patients treated with mixed salts amphetamine extended-release capsules at doses up to 30 mg/day, or placebo, for up to 3 weeks are presented in the following table.

<b>Table 4: Adverse Events Reported by More than 1% of Children aged 6 to 12 years Receiving Fixed Doses of Mixed salts amphetamine extended-release capsules (up to final doses of 10, 20 or 30 mg/day) with an Incidence Greater than Placebo in a Controlled Clinical Study</b>		
	<b>Mixed Salts Amphetamine Extended-Release Capsules (n=374) (%)</b>	<b>Placebo (n=210) (%)</b>
<b>General</b>		
Abdominal pain (stomach ache)	14	10
Fever	5	2
Infection	4	2
Accidental Injury	3	2
Asthenia (fatigue)	2	0
Viral Infection	2	0
<b>Digestive System</b>		
Loss of Appetite	22	2
Vomiting	7	4
Nausea	5	3
Diarrhea	2	1
Dyspepsia	2	1
<b>Nervous System</b>		
Insomnia	17	2
Emotional Lability	9	2
Nervousness	6	2
Dizziness	2	0
<b>Metabolic/Nutritional</b>		
Weight Loss	4	0

Adverse events reported in a 4-week clinical trial in adolescents aged 13 to 17 years treated with mixed salts amphetamine extended-release capsules at doses up to 40 mg/day in adolescents weighing  $\leq 75$  kg/165 lbs, or placebo are presented in the following table.

<b>Table 5: Adverse Events Reported by <math>\geq 1\%</math> or more of Adolescents Weighing <math>\leq 75</math> kg/165 lbs Receiving Mixed salts amphetamine extended-release capsules with Higher Incidence than Placebo in a Forced Weekly-Dose Titration Study<sup>a</sup></b>		
	<b>Mixed Salts Amphetamine Extended-Release Capsules (n=233) (%)</b>	<b>Placebo (n=54) (%)</b>
<b>General</b>		
Abdominal pain (stomach ache)	11	2
Asthenia	3	0
<b>Cardiovascular</b>		
Tachycardia	1	0

<b>Digestive</b>		
Loss of Appetite <sup>b</sup>	36	2
Dry Mouth	4	0
Dyspepsia	3	0
Nausea	3	0
Vomiting	3	0
Diarrhea	2	0
<b>Nervous</b>		
Insomnia <sup>b</sup>	12	4
Nervousness	6	6 <sup>c</sup>
Somnolence	5	4
Emotional Lability	3	0
Depression	1	0
Twitching	1	0
<b>Metabolic/Nutritional</b>		
Weight Loss <sup>b</sup>	9	0
<b>Skin and Appendages</b>		
Herpes Simplex	1	0
<b>Urogenital</b>		
Albuminuria	2	0
Dysmenorrhea	1	0

<sup>a</sup> Included doses up to 40 mg

<sup>b</sup> Dose-related adverse events

<sup>c</sup> Appears the same due to rounding

### Adverse Events Associated with Discontinuation of Treatment

In two placebo-controlled studies of up to 5 weeks duration in children aged 6 to 12 years with ADHD, 2.4% (10/425) of mixed salts amphetamine extended-release capsules treated patients discontinued due to adverse events (including 3 patients with loss of appetite, one of whom also reported insomnia) compared to 2.7% (7/259) receiving placebo. The most frequent adverse events associated with discontinuation of mixed salts amphetamine extended-release capsules in controlled and uncontrolled, multiple-dose clinical trials of pediatric patients (n=595) are presented below. Over half of these patients were exposed to mixed salts amphetamine extended-release capsules for 12 months or more.

**Table 6: Most Frequent Adverse Events Resulting in Discontinuation (>0.5%)**

Adverse Event	% of Pediatric Patients Discontinuing (n=595)
Anorexia (loss of appetite)	2.9
Insomnia	1.5
Weight Loss	1.2
Emotional Lability	1.0
Depression	0.7

In a separate placebo-controlled 4-week study in adolescents aged 13 to 17 years with ADHD, eight patients (3.4%) discontinued treatment due to adverse events among amphetamine extended-release capsules-treated patients (n=233). Three patients discontinued due to insomnia and one

patient each for depression, motor tics, headaches, light-headedness, and anxiety.

### 8.3. Less Common Clinical Trial Adverse Reactions

The following adverse reactions have also been associated with the use of amphetamine, or mixed salts amphetamine:

**Cardiovascular System:** elevation of blood pressure, sudden death, myocardial infarction, stroke, palpitations, tachycardia; there have been isolated reports of cardiomyopathy associated with chronic amphetamine use

**Digestive System:** anorexia, constipation, diarrhea, dryness of the mouth, unpleasant taste, other gastrointestinal disturbances

**Eye Disorders:** mydriasis, vision blurred

**Metabolic and Nutritional:** weight loss

**Nervous System:** aggressive behavior, anger, bruxism, depression, dermatillomania, dizziness, dyskinesia, dysphoria, euphoria, headache, hostility, insomnia, irritability, change in libido, logorrhea, overstimulation, psychotic and manic episodes at recommended doses (e.g., hallucinations, delusional thinking, and mania), paresthesia (including formication), restlessness, tremor, new onset of tics or exacerbation of phonic and motor tics and Tourette's syndrome, seizures

**Skin and Appendages:** alopecia, hypersensitivity reactions including angioedema and anaphylaxis, urticaria, rash. Serious skin rashes, including Stevens-Johnson Syndrome and toxic epidermal necrolysis have been reported.

**Urogenital System:** impotence

**Vascular Disorders:** Raynaud's phenomenon, peripheral coldness

### 8.5 Post-Market Adverse Reactions

The following adverse reactions have been identified during post approval use of amphetamine extended-release capsules. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

**Gastrointestinal Disorders:** intestinal ischemia

**Investigations:** QTc Prolongation

**Vascular Disorders:** epistaxis, contusion

**Suicidal Behavior and Ideation:** There have been post-marketing reports of suicide-related events, including completed suicide, suicide attempt, and suicidal ideation in patients treated with ADHD drugs. In some of these reports, comorbid conditions may have contributed to the event (see [7 WARNINGS AND PRECAUTIONS, Psychiatric, Suicidal Behavior and Ideation](#)).

## 9 DRUG INTERACTIONS

### 9.1 Serious Drug Interactions

#### Serious Drug Interactions

- Co-Administration of Monoamine Oxidase Inhibitors (MAOIs); see [2 CONTRAINDICATIONS, 9.4 Drug-Drug Interactions, Monoamine Oxidase Inhibitors](#)

### 9.2 Drug Interactions Overview

#### Serotonergic Drugs

On rare occasions, serotonin syndrome has occurred in association with the use of amphetamines, such as mixed salts amphetamine extended-release capsules, when given in conjunction with serotonergic drugs, including selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs) (see **7 WARNINGS AND PRECAUTIONS, Serotonin toxicity/Serotonin Syndrome**). It has also been reported in association with overdose of amphetamines, including mixed salts amphetamine extended-release capsules ([see 5 OVERDOSAGE](#)).

As these syndromes may result in potentially life-threatening conditions (characterized by clusters of symptoms such as hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, mental status changes including confusion, irritability, extreme agitation progressing to delirium and coma), treatment with serotonergic drugs should be discontinued if such events occur and supportive symptomatic treatment should be initiated. TARO-AMPHETAMINE XR should be used with caution in combination with serotonergic and/or neuroleptic drugs (e.g. triptans, certain tricyclic antidepressants and opiate analgesics, lithium, St. John's Wort, MAOI) due to the risk of serotonin syndrome (see [7 WARNINGS AND PRECAUTIONS, Serotonin toxicity/Serotonin Syndrome](#)).

### 9.4 Drug-Drug Interactions

The drugs listed below are based on either drug interaction case reports or studies, or potential interactions due to the expected magnitude and seriousness of the interaction (i.e., those identified as contraindicated).

**Acidifying agents:** Gastrointestinal acidifying agents (e.g., guanethidine, reserpine, glutamic acid HCl, ascorbic acid, etc.) may lower absorption of amphetamines.

**Urinary acidifying agents:** (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion. Both groups of agents lower blood levels and efficacy of amphetamines.

**Adrenergic blockers:** As expected by their pharmacologic action, adrenergic blockers are inhibited by amphetamines.

**Alkalinizing agents:** Gastrointestinal alkalinizing agents (sodium bicarbonate, etc.), may increase absorption of amphetamines. Co-administration of TARO-AMPHETAMINE XR and gastrointestinal alkalinizing agents, such as antacids, should be avoided. Urinary alkalinizing agents (acetazolamide, some thiazides) increase the concentration of the non-ionized species of the amphetamine molecule, thereby decreasing urinary excretion. Both groups of agents increase blood levels and therefore potentiate the actions of amphetamines.

**Proton Pump Inhibitors:** Proton Pump Inhibitors act on proton pumps by blocking acid production thereby

reducing gastric acidity. In the presence of a proton pump inhibitor, the median  $T_{max}$  of mixed salts amphetamine extended-release capsules was shortened from 5 hours to 2.75 hours. Therefore, co-administration of TARO-AMPHETAMINE XR and proton pump inhibitors should be avoided.

Antidepressants, tricyclic: Amphetamines may enhance the activity of tricyclic antidepressant or sympathomimetic agents; *d*-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of *d*-amphetamine in the brain; cardiovascular effects can be potentiated.

MAO inhibitors: Monoamine oxidase inhibitor antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism. This slowing potentiates amphetamines, increasing their effect on the release of norepinephrine and other monoamines from adrenergic nerve endings; this can cause headaches and other signs of hypertensive crisis. A variety of neurological toxic effects and malignant hyperpyrexia can occur, sometimes with fatal results.

Antihistamines: Amphetamines may counteract the sedative effect of some antihistamines.

Antihypertensives: Amphetamines may antagonize the hypotensive effects of antihypertensives.

Chlorpromazine: Chlorpromazine blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of amphetamines, and can be used to treat amphetamine poisoning.

Ethosuximide: Amphetamines may delay intestinal absorption of ethosuximide.

Haloperidol: Haloperidol blocks dopamine receptors, thus inhibiting the central stimulant effects of amphetamines.

Lithium carbonate: The anorectic and stimulatory effects of amphetamines may be inhibited by lithium carbonate.

Meperidine: Amphetamines potentiate the analgesic effect of meperidine.

Methenamine therapy: Urinary excretion of amphetamines is increased, and efficacy is reduced, by acidifying agents used in methenamine therapy.

Norepinephrine: Amphetamines enhance the adrenergic effect of norepinephrine.

Phenobarbital: Amphetamines may delay intestinal absorption of phenobarbital; co-administration of phenobarbital may produce a synergistic anticonvulsant action.

Phenytoin: Amphetamines may delay intestinal absorption of phenytoin; co-administration of phenytoin may produce a synergistic anticonvulsant action.

Propoxyphene: In cases of propoxyphene overdose, amphetamine CNS stimulation is potentiated and fatal convulsions can occur.

Veratrum alkaloids: Amphetamines inhibit the hypotensive effect of veratrum alkaloids.

## 9.5 Drug-Food Interactions

Food does not affect the extent of absorption of TARO-AMPHETAMINE XR capsules, but prolongs  $T_{max}$  by 2.5 hours. Opening the capsule and sprinkling the contents on applesauce results in comparable absorption to the intact capsule taken in the fasted states.

## 9.6 Drug-Herb Interactions

Interactions with herbal products have not been established.

## 9.7 Drug-Laboratory Test Interactions

Amphetamines can cause a significant elevation in plasma corticosteroid levels. This increase is greatest in the evening. Amphetamines may interfere with urinary steroid determinations.

TARO-AMPHETAMINE XR can interfere with the test results from certain radioactive diagnostic agents (such as those used in dopamine transporter (DAT) visualization, e.g. DATSCAN [ioflupane I-123]) and lead to false-positive diagnostic results (false abnormal DAT binding results).

## 10 CLINICAL PHARMACOLOGY

### 10.1 Mechanism of Action

TARO-AMPHETAMINE XR (mixed salts amphetamine extended-release capsules) is a once a day product containing immediate-release and delayed-release pellets that has been shown to provide a double-pulsed delivery of amphetamine in patients with ADHD.

Amphetamines are non-catecholamine sympathomimetic amines with CNS stimulant activity. The mode of therapeutic action in Attention Deficit Hyperactivity Disorder (ADHD) is not known. Amphetamines are thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space.

### 10.2 Pharmacodynamics

The behavioral manifestations of ADHD are believed to involve an interactive imbalance between dopaminergic and other neurotransmitter systems. However, a fundamental dopaminergic dysfunction appears to have special significance. Amphetamine increases the availability of synaptic dopamine at key sites in the brain by stimulating its release from newly synthesized (cytoplasmic) dopamine pools. Thus, unlike methylphenidate, which increases dopamine availability primarily by blocking reuptake, amphetamine's effect does not appear to be highly dependent on impulse-released dopamine.

This primary mechanism of action of amphetamine is supported by experiments with reserpine and  $\alpha$ -methyltyrosine. Pretreatment with reserpine, which is believed to reduce stored vesicular (but not cytoplasmic) dopamine, was ineffective in attenuating responses to amphetamine challenge. In contrast, the depletion of newly synthesized cytoplasmic dopamine through the inhibition of tyrosine hydroxylase (the rate limiting anabolic enzyme) using  $\alpha$ -methyltyrosine, did reduce responses following amphetamine challenge.

Systemically administered amphetamine produced stimulation of dopamine release from the nucleus accumbens and dorsal caudate. Administration of a low acute dose of amphetamine produced a region-specific decrease in dopamine from the "shell" in comparison to the "core" regions of the nucleus accumbens. Higher acute doses increased extracellular dopamine to the same extent in both regions.

In addition to a dopaminergic mechanism of action, there is experimental evidence to suggest involvement of other neurotransmitter systems in the regulation of behavioral effects (e.g., motor activity). These include interactions between dopaminergic, GABAergic and glutamatergic pathways and possible involvement of cholinergic pathways.

Amphetamine-induced effects are primarily mediated by D<sub>1</sub> and D<sub>2</sub> receptors. In addition, 5-HT<sub>2A</sub> and 5-HT<sub>3</sub> receptors, and NMDA receptors are suggested to play a role in amphetamine-induced release of dopamine, and in the regulation of the firing rate and pattern of midbrain dopamine neurons, respectively.

Prenatal exposure to amphetamine was associated with a variety of responses in offspring that included

increases in conditioned avoidance, exploratory behavior, and sexual behavior, and decreases in 5-HT content in the medial hypothalamus.

Repeated administration of high concentrations of amphetamine produced striatal, neostriatum, and frontal cortex dopamine nerve fiber degeneration.

Amphetamine interacted with a variety of compounds that included caffeine, cocaine, morphine, diazepam, phencyclidine, clonidine, fluoxetine, lithium, pentobarbital, ethanol, and THC. The mechanism of many of these interactions is currently not known.

### 10.3 Pharmacokinetics

#### Pharmacokinetic Results in Healthy Adult and Pediatric Subjects


Following oral administration of a single dose of mixed salts amphetamine extended-release capsules) in healthy adult subjects, peak plasma concentrations ( $C_{max}$ ) of 28.1 ng/mL and 8.7 ng/mL occurred in about 7 hours for *d*-amphetamine and 8 hours for *l*-amphetamine, respectively. The  $AUC_{0-inf}$  for *d*-amphetamine and *l*-amphetamine were 567 ng•hr/mL and 203 ng•hr/mL, respectively (see table 7).

The mean elimination half-life is 1 hour shorter for *d*-amphetamine and 2 hours shorter for *l*-amphetamine in children aged 6 to 12 years compared to that in adults ( $t_{1/2}$  is 10 hours for *d*-amphetamine and 13 hours for *l*-amphetamine in adults, and 9 hours and 11 hours, respectively, for children). Children had higher systemic exposure to amphetamine ( $C_{max}$  and AUC) than adults for a given dose of mixed salts amphetamine extended-release capsules, which was attributed to the higher dose administered to children on a mg/kg body weight basis compared to adults. Upon dose normalization on a mg/kg basis, children showed 30% less systemic exposure compared to adults.

**Table 7: Pharmacokinetic Parameters for Single 20 mg Dose of mixed salts amphetamine extended-release capsules**

Treatment	<i>d</i> -amphetamine			<i>l</i> -amphetamine		
	$AUC_{0-inf}$ (ng•hr/mL)	$T_{max}$ (hours)	$C_{max}$ (ng/mL)	$AUC_{0-inf}$ (ng•hr/mL)	$T_{max}$ (hours)	$C_{max}$ (ng/mL)
Mixed Salts Amphetamine Extended-Release Capsules (20 mg, qd)	567	7.0	28.1	203	8.2	8.7

**Figure 1: Mean *d*-amphetamine and *l*-amphetamine Plasma Concentrations following a single 20mg morning Administration of Mixed salts amphetamine extended-Release Capsules in the Fed State.**



### Food Effect Study in Healthy Adult Subjects

A single-dose study compared the relative bioavailability of *d*-amphetamine and *l*-amphetamine following administration of a single 30 mg dose of mixed salts amphetamine extended-release capsules fasted, fed (high-fat meal) and sprinkled on food (otherwise fasted) in 21 healthy adult subjects. Food does not affect the extent of absorption of mixed salts amphetamine extended-release capsules, but prolongs  $T_{max}$  by 2.5 hours (from 5.2 hours at fasted state to 7.7 hours after a high-fat meal). Opening the capsule and sprinkling the contents on applesauce results in comparable absorption to the intact capsule taken in the fasted states.

### Absorption

Pharmacokinetic studies of mixed salts amphetamine extended-release capsules have been conducted in healthy adult and pediatric (aged 6 to 12 years) subjects, and adolescent (aged 13 to 17 years) and pediatric patients with ADHD. Mixed salts amphetamine extended-release capsules contain dextroamphetamine (*d*-amphetamine) and levoamphetamine (*l*-amphetamine) salts in the ratio of 3:1.

Mixed salts amphetamine extended-release capsules demonstrates linear pharmacokinetics over the dose range of 20 to 60 mg in adults and adolescents aged 13 to 17 years weighing greater than 75 kg/165 lbs, over the dose range of 10 to 40 mg in adolescents weighing less than or equal to 75 kg/165 lbs and 5 to 30 mg in children aged 6 to 12 years. There was no unexpected accumulation at steady state.

Comparison of the pharmacokinetics of *d*- and *l*-amphetamine after oral administration of mixed salts amphetamine extended-release capsules in pediatric (aged 6 to 12 years) and adolescent (aged 13 to 17 years) ADHD patients and healthy adult volunteers indicates that body weight is the primary determinant

of apparent differences in the pharmacokinetics of *d*- and *l*-amphetamine across the age range. Systemic exposure measured by area under the curve to infinity ( $AUC_{\infty}$ ) and maximum plasma concentration ( $C_{max}$ ) decreased with increases in body weight, while oral volume of distribution ( $V_z/F$ ), oral clearance ( $CL/F$ ), and elimination half-life ( $t_{1/2}$ ) increased with increases in body weight.

### Distribution

Literature studies indicated a stereospecific distribution of the individual dextro (*d*-) and levo (*l*-) enantiomers of amphetamine in the brain and heart of mice. Distribution kinetics in the rat indicated that similar amounts of both enantiomers were excreted in the urine as parent drug and as the hydroxy metabolite.

Radiolabelled  $^3H$ -*d*-amphetamine was distributed in many tissues of pregnant and non-pregnant female and male mice. Amphetamine crossed the placenta and was present in the placenta, whole fetus, and in fetal brain and liver. Fetal tissue concentrations were generally much lower than maternal tissue concentrations.

### Metabolism

Amphetamine is reported to be oxidized at the 4 position of the benzene ring to form 4-hydroxyamphetamine, or on the side chain  $\alpha$  or  $\beta$  carbons to form alpha-hydroxy-amphetamine or norephedrine, respectively. Norephedrine and 4-hydroxy-amphetamine are both active and each is subsequently oxidized to form 4-hydroxy-norephedrine. Alpha-hydroxy-amphetamine undergoes deamination to form phenylacetone, which ultimately forms benzoic acid and its glucuronide and the glycine conjugate hippuric acid. Although the enzymes involved in amphetamine metabolism have not been clearly defined, CYP2D6 is known to be involved with formation of 4-hydroxy-amphetamine. Since CYP2D6 is genetically polymorphic, population variations in amphetamine metabolism are a possibility.

Amphetamine is known to inhibit monoamine oxidase, whereas the ability of amphetamine and its metabolites to inhibit various P450 isozymes and other enzymes has not been adequately elucidated. In vitro experiments with human microsomes indicate minor inhibition of CYP2D6 by amphetamine and minor inhibition of CYP1A2, 2D6, and 3A4 by one or more metabolites. However, due to the probability of auto-inhibition and the lack of information on the concentration of these metabolites relative to in vivo concentrations, no predications regarding the potential for amphetamine or its metabolites to inhibit the metabolism of other drugs by CYP isozymes in vivo can be made.

Metabolism of amphetamine was affected by induction of the CYP450 system with phenobarbital. The direct benzene ring hydroxylation of parent drug was mediated by CYP2D1 in the rat and by the human homologue, CYP2D6, in human microsomes. The deamination of amphetamine was shown to be mediated by the CYP isoform 2C3 from the rabbit, but not the 2C11 and 2C13 isoforms from the rat. N-oxygenation of amphetamine to the hydroxylamine and oxime metabolites was demonstrated in vitro with flavin containing monooxygenase Form 3 from humans.

### Elimination

With normal urine pHs approximately half of an administered dose of amphetamine is recoverable in urine as derivatives of alpha-hydroxy-amphetamine and approximately another 30%-40% of the dose is recoverable in urine as amphetamine itself. Since amphetamine has a pKa of 9.9, urinary recovery of amphetamine is highly dependent on pH and urine flow rates. Alkaline urine pHs result in less ionization and reduced renal elimination, and acidic pHs and high flow rates result in increased renal elimination with clearances greater than glomerular filtration rates, indicating the involvement of active secretion. Urinary recovery of amphetamine has been reported to range from 1% to 75%, depending on urinary pH, with the

remaining fraction of the dose hepatically metabolized. Consequently, both hepatic and renal dysfunction have the potential to inhibit the elimination of amphetamine and result in prolonged exposures. In addition, drugs that affect urinary pH are known to alter the elimination of amphetamine, and any decrease in amphetamine's metabolism that might occur due to drug interactions or genetic polymorphisms is more likely to be clinically significant when renal elimination is decreased (see [7 WARNINGS AND PRECAUTIONS, Renal](#); [9.4 Drug-Drug Interactions](#)).

In rats, the urinary excretion of amphetamine and its major rat metabolite, 4-hydroxyamphetamine, was influenced by strain of rat, significant differences occurring between poor metabolizer versus extensive metabolizer strains.

### Special Populations and Conditions

- **Pediatrics**

#### Pharmacokinetic Results in Children and Adolescents with ADHD

In a 20 mg single-dose study in 51 children (aged 6 to 12 years) with ADHD, the mean  $T_{max}$  for *d*-amphetamine was 6.8 hours and the mean  $C_{max}$  was 48.8 ng/mL. The corresponding mean  $T_{max}$  and  $C_{max}$  values for *l*-amphetamine were 6.9 hours and 14.8 ng/mL, respectively. The mean elimination half-life for *d*-amphetamine and *l*-amphetamine was 9.5 and 10.9 hours, respectively. Following dosing of children with ADHD to steady state with mixed salts amphetamine extended-release capsules 10, 20 and 30 mg, the mean *d*-amphetamine  $C_{max}$  (ng/mL) in plasma for mixed salts amphetamine extended-release capsules was 28.8 (10 mg), 54.6 (20 mg) and 89.0 (30 mg). For *l*-amphetamine, the mean  $C_{max}$  values for the three mixed salts amphetamine extended-release capsules doses were 8.8, 17.2 and 28.1 ng/mL, respectively.

In adolescents aged 13-17 years and weighing less than or equal to 75 kg/165 lbs, the mean elimination half-life for *d*-amphetamine is 11 hours, and 13-14 hours for *l*-amphetamine.

**Table 8: Mixed salts amphetamine extended-release capsules Pharmacokinetic Parameters at Steady State in Children with ADHD**

Treatment	<i>d</i> -amphetamine			<i>l</i> -amphetamine		
	AUC <sub>0-24</sub> (ng•hr/mL)	T <sub>max</sub> (hours)	C <sub>max</sub> (ng/mL)	AUC <sub>0-24</sub> (ng•hr/mL)	T <sub>max</sub> (hours)	C <sub>max</sub> (ng/mL)
Mixed Salts Amphetamine Extended-Release Capsules (10 mg)	432	6.4	28.8	138	6.4	8.8
Mixed Salts Amphetamine Extended-Release Capsules (20 mg)	777	5.8	54.6	262	5.7	17.2

Mixed Salts Amphetamine Extended-Release Capsules (30 mg)	1364	5.5	89.0	444	5.5	28.1
--	------	-----	------	-----	-----	------

- **Renal Insufficiency**

In a pharmacokinetic study of lisdexamfetamine in subjects with normal and impaired renal function, *d*-amphetamine clearance was reduced from 0.7 L/hr/kg in normal subjects to 0.4 L/hr/kg in subjects with severe renal impairment (GFR 15 to < 30 mL/min/1.73 m<sup>2</sup>). *D*-amphetamine is not dialyzable. (see [7 WARNINGS AND PRECAUTIONS, Renal](#); [4 DOSAGE AND ADMINISTRATION](#)).

## 11 STORAGE, STABILITY AND DISPOSAL

Store at 20°-25°C; excursions permitted 15°-30°C; dispense in tight, light-resistant container. Any unused medicinal product should be disposed of in accordance with local requirements.

**PART II: SCIENTIFIC INFORMATION****13 PHARMACEUTICAL INFORMATION****Drug Substance**



Proper name:

1. *d*-amphetamine Saccharate
2. Amphetamine Aspartate Monohydrate
3. *d*-amphetamine Sulfate USP
4. Amphetamine Sulfate USP

Chemical name:




1. Phenyl-2-(*S*)-aminopropane saccharate
2. Phenyl-2-(*R,S*)-aminopropane aspartate monohydrate
3. phenyl-2-(*S*)-aminopropane sulfate, phenyl 2-(*S*) aminopropane sulfate, Benzeneethanamine,  $\alpha$ -methyl-, (*S*)-, sulfate (2:1)
4. phenyl-2-(*R,S*)-aminopropane sulfate, phenyl 2-(*R,S*) aminopropane sulphate milled, Benzeneethanamine,  $\alpha$ -methyl-, sulfate (2:1), ( $\pm$ )

Structural formula, Molecular formula and molecular weights:


1) *d*-amphetamine Saccharate

480.6 g/mol

## 2) Amphetamine Aspartate Monohydrate

3) *d*-amphetamine Sulfate

## 4) Amphetamine Sulfate



Physicochemical properties: The four amphetamine salts are white to off-white, crystalline powder. The amphetamine sulfate and *d*-amphetamine sulfate is freely soluble in water and slightly soluble in alcohol, amphetamine aspartate monohydrate is freely soluble in water and soluble in alcohol and ether and *d*-amphetamine saccharate is freely soluble in water. Also, the amphetamine salts are known to be stable molecules.

## 14 CLINICAL TRIALS

### 14.1 Clinical Trials by Indication

#### Treatment of ADHD in Children (6 – 12 years of age)

**Table 9 - Summary of patient demographics for clinical trials in children (6 – 12 years of age)**

Study #	Study design	Dosage, route of administration and duration	Study subjects (n)	Mean age (Range)	Sex
SLI381.301	double-blind, randomized, placebo-controlled, parallel-group study	Mixed salts amphetamine extended-release capsules 10, 20, or 30 mg or placebo Oral, QD for three weeks	584	8.6 (6 to 12) years	Male (77%) and Female (23%)
SLI381.201	double-blind, randomized, placebo- and active-controlled crossover study	Mixed salts amphetamine extended-release capsules 10, 20, or 30 mg or placebo or Mixed salts amphetamine extended-release capsules 10 mg Oral, QD for one week*	51	9.5 (6 to 12) years	Male (86%) and Female (14%)

\*Each subject was randomized to sequentially taking each of the 5 treatments for one week, for a total of 5 weeks

A double-blind, randomized, placebo-controlled, parallel-group study of 584 children aged 6 to 12 years who met DSM-IV criteria for ADHD (either combined type or hyperactive-impulsive type) was conducted in a naturalistic setting. Patients were randomized to fixed dose treatment groups receiving final doses of 10, 20, or 30 mg/day of mixed salts amphetamine extended-release capsules or placebo. Mixed salts amphetamine extended-release capsules or placebo was taken once daily in the morning for three weeks. Significant improvements in patient behavior, based upon teacher and parent ratings of attention and hyperactivity, were observed for all mixed salts amphetamine extended-release capsules doses compared to patients who received placebo, for all three weeks, including the first week of treatment, when all mixed salts amphetamine extended-release capsules subjects were receiving a titration dose of 10 mg/day. Patients who received mixed salts amphetamine extended-release capsules showed behavioral improvements within the first week of treatment ( $p < 0.001$ ) and in both morning ( $p < 0.001$ ) and afternoon ( $p < 0.001$ ) compared to patients on placebo.

A double-blind, randomized, placebo- and active-controlled crossover study of 51 children aged 6 to 12 years with ADHD was conducted in a classroom laboratory setting. In comparison to placebo, amphetamine extended-release capsules 10, 20, and 30 mg/day showed rapid improvement and continued significant efficacy ( $p < 0.05$ ) up to 12 hours post-dose for all cognitive and behavioral measures.

In these two clinical trials conducted in different settings, mixed salts amphetamine extended-release capsules taken once in the morning demonstrated efficacy in the treatment of ADHD (either combined type or hyperactive-impulsive type) for at least 12 hours.

### Treatment of ADHD in Adolescents (13 - 17 years of age)

**Table 10 - Summary of patient demographics for clinical trials in adolescents (13 – 17 years of age)**

Study #	Study design	Dosage, route of administration and duration	Study subjects (n)	Mean age (Range)	Sex
SLI381.314a	double-blind, randomized, multi-center, parallel-group, placebo-controlled study	Mixed salts amphetamine extended-release capsules 10, 20, 30, 40, 50, or 60 mg or placebo Oral, QD for four weeks	327	14.2 (13 to 17) years	Male (65%) and Female (35%)

A double-blind, randomized, multi-center, parallel-group, placebo-controlled study was conducted in adolescents aged 13-17 years (n=327) who met DSM-IV criteria for ADHD. The primary cohort of patients (n=287, weighing ≤75 kg/165 lbs) was randomized to fixed dose treatment groups and received four weeks of treatment. Patients were randomized to receive final doses of 10 mg, 20 mg, 30 mg, and 40 mg mixed salts amphetamine extended-release capsules or placebo once daily in the morning; patients randomized to doses greater than 10mg were titrated to their final doses by 10 mg each week. The secondary cohort consisted of 40 subjects weighing >75 kg/165 lbs who were randomized to fixed dose treatment groups receiving final doses of 50 mg and 60 mg mixed salts amphetamine extended-release capsules or placebo once daily in the morning for 4 weeks. The primary efficacy variable was the ADHD-RS-IV total scores for the primary cohort. Improvements in the primary cohort were statistically significantly greater in all four primary cohort active treatment groups (mixed salts amphetamine extended-release capsules 10 mg, 20 mg, 30 mg, and 40 mg) compared with the placebo group. Mixed salts amphetamine extended-release capsules at doses of 10-40 mg is effective in the treatment of ADHD in adolescents weighing ≤75 kg/165 lbs. There was not adequate evidence that doses greater than 20 mg/day conferred additional benefit.

**Treatment of ADHD in Adults (18 years of age or older)****Table 11 - Summary of patient demographics for clinical trials in adults (18 years of age or older)**

Study #	Study design	Dosage, route of administration and duration	Study subjects (n)	Mean age (Range)	Sex
SLI381.303	double-blind, randomized, placebo-controlled, parallel-group study	Mixed salts amphetamine extended-release capsules 20, 40, or 60 mg or placebo Oral, QD for four weeks	255	39.2 (18 to 76) years	Male (60%) and Female (40%)
SLI381.304	Long-term, multi-center, open-label extension study	mixed salts amphetamine extended-release capsules XR20, 40, or 60 mg or placebo Oral, QD for twelve months	223	39.8 (18 to 76) years	Male (59%) and Female (41%)

A double-blind, randomized, placebo-controlled, parallel-group study of 255 adults who met DSM-IV criteria for ADHD was conducted. Patients were randomized to fixed dose treatment groups receiving final doses of 20, 40 or 60 mg/day of mixed salts amphetamine extended-release capsules or placebo. Mixed salts amphetamine extended-release capsules or placebo was taken once daily in the morning for four weeks. Significant improvements in patient symptoms of inattention and impulsivity/hyperactivity, based upon the 18-item total ADHD symptom score, were observed at endpoint for all mixed salts amphetamine extended-release capsules doses compared to patients who received placebo for all four weeks ( $p < 0.001$ ). There was not adequate evidence that doses greater than 20 mg/day conferred additional benefit.

A long-term, open-label extension of the above-mentioned clinical study was conducted in 223 adult patients. At 12 months, all patients showed continuing symptomatic improvement as measured by the 18 item total ADHD symptom score.

**14.2 Comparative Bioavailability Studies****Bioequivalence of 1 x 20 mg Capsule to 4 x 5 mg Capsules (Children with ADHD)**

In a single dose study in 20 children (aged 6 to 12 years) with ADHD, a single administration of four 5 mg capsules of Mixed salts amphetamine extended-release capsules was shown to be bioequivalent to a single 20 mg capsule for both d- and l-amphetamine under fasting conditions.

<b>Table 12 - Pharmacokinetic Parameters for Mixed salts amphetamine extended-release capsules</b>				
<b>Summary Table of the Comparative Bioavailability Data</b>				
<b>Mixed salts amphetamine extended-release capsules 4 x 5 mg Capsules vs 1 x 20 mg Capsule - Under Fasting Conditions From Measured Data</b>				
Parameter	Geometric Mean Arithmetic Mean (CV%)		% Ratio of Geometric Means	Confidence Interval (90% CI)
	Mixed salts amphetamine extended-release capsules 4x5mg capsules	Mixed salts amphetamine extended-release capsules 1x20mg capsules		
<b>d-amphetamine</b>				
AUC <sub>T</sub> (ng•h/mL)	823.5 843.5 (22.2%)	775.7 794.8 (22.6%)	106.2	101.0 -111.6
AUC <sub>I</sub> (ng•h/mL)	845.8 863.9 (21.1%)	797.8 815.3 (21.4%)	106.0	101.5 -110.7
C <sub>max</sub> (ng/mL)	50.4 51.9 (24.5%)	49.9 51.9 (28.9%)	101.0	92.4 -110.3
T <sub>max</sub> <sup>a</sup> (h)	4.65 (50.0%)	4.50 (37.8%)		
T <sub>1/2</sub> <sup>a</sup> (h)	8.10 (14.5%)	7.98 (17.0%)		
<b>l-amphetamine</b>				
AUCT (ng•h/mL)	276.8 286.2 (26.4%)	238.5 247.0 (27.1%)	116.0	108.6 -124.0
AUC <sub>I</sub> (ng•h/mL)	297.1 304.0 (22.3%)	263.7 269.6 (21.7%)	112.7	107.6 -118.0
C <sub>max</sub> (ng/mL)	16.2 16.7 (24.1%)	15.2 15.8 (28.6%)	106.6	98.5 -115.3
T <sub>max</sub> <sup>a</sup> (h)	4.95 (50.1%)	4.85 (39.7%)		
T <sub>1/2</sub> <sup>a</sup> (h)	9.16 (14.5%)	9.13 (18.5%)		

<sup>a</sup> Arithmetic mean (CV%)

For both d- and l- amphetamine, statistically significant differences were noted between the two treatment groups for AUC, with the 4 x 5mg group showing higher AUC, but not for C<sub>max</sub> and T<sub>max</sub>.

### 14.3 Comparative Bioavailability Studies

A single-dose (1 x 30 mg), randomized, three-period, three-treatment, crossover comparative bioavailability study of TARO-AMPHETAMINE XR 30 mg extended-release capsules (Sun Pharma Canada Inc.), Adderall XR<sup>®</sup> 30 mg extended-release capsules (Shire US Inc.) and Adderall XR 30 mg extended-release capsules (Shire Pharma Canada ULC) was conducted in healthy, adult male and female subjects under fasting conditions. Comparative bioavailability data of TARO-AMPHETAMINE XR 30 mg extended-release capsules (Sun Pharma Canada Inc.) and ADDERALL XR 30 mg extended-release capsules (Shire Pharma Canada ULC) from the 35 subjects that were included in the statistical analysis are presented in the following tables.

#### SUMMARY TABLES OF THE COMPARATIVE BIOAVAILABILITY DATA

<i>d</i> -amphetamine (1 x 30 mg) Geometric Mean Arithmetic Mean (CV %)				
Parameter	Test <sup>1</sup>	Reference <sup>2</sup>	% Ratio of Geometric Means	90% Confidence Interval
AUC <sub>T</sub> (ng·h/mL)	751.9 763.0 (20.5)	771.9 784.5 (19.8)	97.4	94.0 - 100.9
AUC <sub>I</sub> (ng·h/mL)	779.3 792.2 (22.0)	802.8 817.3 (21.0)	97.1	93.4 - 100.9
C <sub>max</sub> (ng/mL)	41.2 41.6 (16.7)	42.8 43.5 (19.2)	96.2	93.4 - 99.1
T <sub>max</sub> <sup>3</sup> (h)	4.5 (3.0 – 8.5)	4.5 (3.0 – 11.0)		
T <sub>½</sub> <sup>4</sup> (h)	11.6 (17.8)	12.1 (17.3)		

<sup>1</sup> TARO-AMPHETAMINE XR (mixed salts amphetamine) extended-release capsules 30 mg (Sun Pharma Canada Inc.)

<sup>2</sup> Adderall XR® (mixed salts amphetamine) extended-release capsules 30 mg (Shire Pharma Canada ULC)

<sup>3</sup> Expressed as median (range)

<sup>4</sup> Expressed as the arithmetic mean (CV %) only

<i>l</i> -amphetamine (1 x 30 mg) Geometric Mean Arithmetic Mean (CV %)				
Parameter	Test <sup>1</sup>	Reference <sup>2</sup>	% Ratio of Geometric Means	90% Confidence Interval
AUC <sub>T</sub> (ng·h/mL)	268.5 272.8 (21.4)	276.2 281.0 (20.6)	97.2	93.6 - 101.0
AUC <sub>I</sub> (ng·h/mL)	287.8 294.3 (26.0)	298.5 305.1 (23.3)	96.4	92.0 - 100.9
C <sub>max</sub> (ng/mL)	12.5 12.6 (16.6)	13.1 13.3 (20.1)	95.4	92.7 - 98.2
T <sub>max</sub> <sup>3</sup> (h)	5.0 (3.0 - 8.5)	5.0 (3.5 - 11.0)		
T <sub>½</sub> <sup>4</sup> (h)	14.4 (25.3)	15.3 (21.4)		

<sup>1</sup> TARO-AMPHETAMINE XR (mixed salts amphetamine) extended-release capsules 30 mg (Sun Pharma Canada Inc.)

<sup>2</sup> Adderall XR® (mixed salts amphetamine) extended-release capsules 30 mg (Shire Pharma Canada ULC)

<sup>3</sup> Expressed as median (range)

<sup>4</sup> Expressed as the arithmetic mean (CV %) only

A single-dose (1 x 30 mg), randomized, two-period, two-treatment, crossover comparative bioavailability study of TARO-AMPHETAMINE XR 30 mg extended-release capsules (Sun Pharma Canada Inc.) and Adderall XR 30 mg extended-release capsules (Shire US Inc.) was conducted in healthy, adult male and female subjects under fed conditions. Comparative bioavailability data from the 39 subjects that were included in the statistical analysis are presented in the following tables:

SUMMARY TABLES OF THE COMPARATIVE BIOAVAILABILITY DATA

<i>d</i> -amphetamine (1 x 30 mg) Geometric Mean Arithmetic Mean (CV %)				
Parameter	Test <sup>1</sup>	Reference <sup>2</sup>	% Ratio of Geometric Means	90 % Confidence Interval
AUC <sub>T</sub> (ng·h/mL)	737.5 746.2 (15.9)	741.4 751.6 (17.6)	99.5	96.7 – 102.3
AUC <sub>I</sub> <sup>3</sup> (ng·h/mL)	788.5 804.8 (22.8)	785.4 799.7 (20.2)	100.4	96.5 – 104.5
C <sub>max</sub> (ng/mL)	34.4 34.8 (16.6)	32.0 32.9 (23.5)	107.5	102.6 – 112.6
T <sub>max</sub> <sup>4</sup> (h)	9.5 (4.5-12.0)	7.5 (3.0 -24.0)		
T <sub>½</sub> <sup>3,5</sup> (h)	13.3 (29.6)	13.1 (22.7)		

<sup>1</sup> TARO-AMPHETAMINE XR (mixed salts amphetamine) extended-release capsules 30 mg (Sun Pharma Canada Inc.)

<sup>2</sup> Adderall XR® (mixed salts amphetamine) extended-release capsules 30 mg (Shire US Inc.)

<sup>3</sup>n=38

<sup>4</sup> Expressed as median (range)

<sup>5</sup> Expressed as the arithmetic mean (CV %) only

<i>l</i> -amphetamine (1 x 30 mg) Geometric Mean Arithmetic Mean (CV %)				
Parameter	Test <sup>1</sup>	Reference <sup>2</sup>	% Ratio of Geometric Means	90% Confidence Interval
AUC <sub>T</sub> (ng·h/mL)	254.1 258.2 (18.7)	250.5 254.5 (18.2)	101.5	98.6 – 104.3
AUC <sub>I</sub> (ng·h/mL)	280.3 286.8 (22.3)	276.7 283.1 (22.4)	101.3	98.2 – 104.5
C <sub>max</sub> (ng/mL)	10.6 10.8 (18.0)	9.7 10.0 (23.5)	109.9	105.1 – 114.9
T <sub>max</sub> <sup>3</sup> (h)	9.5 (5.5-12.0)	8.0 (3.5-24.0)		
T <sub>½</sub> <sup>4</sup> (h)	15.8 (23.9)	16.3 (26.8)		

<sup>1</sup> TARO-AMPHETAMINE XR (mixed salts amphetamine) extended-release capsules 30 mg (Sun Pharma Canada Inc.)

<sup>2</sup> Adderall XR® (mixed salts amphetamine) extended-release capsules 30 mg (Shire US Inc.)

<sup>3</sup> Expressed as median (range)

<sup>4</sup> Expressed as the arithmetic mean (CV %) only

## 16 NON-CLINICAL TOXICOLOGY

### Acute Toxicity Studies

The acute LD<sub>50</sub> amphetamine is as follows:

**Table 13 – Acute LD<sub>50</sub> for amphetamine**

Species	LD <sub>50</sub> (mg/kg)
Mice (i.v.)	52
Mice (oral)	353
Rat (i.p.)	70
Dog (i.v.)	8.5
Monkey (i.v., oral)	5

Acute toxicity studies conducted in mice, rats, dogs and monkeys showed similar dose-dependent responses. The order for comparative toxicity ranking, based upon the LD<sub>50</sub> values, was monkey>dog>mouse.

Acute toxicity to dextro (*d*-), and levo (*l*-) amphetamine was age-dependent. Young mice (3-30 days old) tolerated higher doses (up to 180 mg/kg i.p.) than adults. Toxicity increased from 18-days of age onward. Mortality response curves were biphasic for developing mice and polyphasic for adult mice.

Acute toxicity signs noted in mice (25-75 mg/kg i.v.), rats (45-178 mg/kg i.p.), dogs (5-9 mg/kg i.v.) and monkeys (1-6 mg/kg i.v.) included marked to severe hyperactivity, stereotypic behavior, mild to marked clonic and/or tonic convulsions, and (in monkeys) marked increase in respiratory rate, body temperature and pupil size. Death was associated with convulsions and, in dogs, massive endocardial hemorrhages in both ventricles.

### Subacute and Subchronic Toxicity Studies

Subacute and subchronic toxicity signs noted in mice (0-2000 ppm of *d,l*-amphetamine in feed) and rats (0-750 ppm of *d,l*-amphetamine in feed) from 14-day and 13-week dietary studies included hyperactivity, decreased body weight and food consumption. Deaths in the order of 15 to 65% were reported in mice administered 500-2000 ppm of *d,l*-amphetamine in feed. No treatment-related deaths occurred in the rat study.

### Genotoxicity

Amphetamine, in the enantiomer ratio present in mixed salts amphetamine extended-release capsules (*d*- to *l*- ratio of 3:1), was not clastogenic in the mouse bone marrow micronucleus test in vivo and was negative when tested in the *E. coli* component of the Ames test in vitro. *d,l*-Amphetamine (1:1 enantiomer ratio) has been reported to produce a positive response in the mouse bone marrow micronucleus test, an equivocal response in the Ames test, and negative responses in the in vitro sister chromatid exchange and chromosomal aberration assays.

### Carcinogenicity

No evidence of carcinogenicity was found in studies in which *d,l*-amphetamine (enantiomer ratio of 1:1) was administered to mice and rats in the diet for 2 years at doses of up to 30 mg/kg/day in male mice, 19 mg/kg/day in female mice, and 5 mg/kg/day in male and female rats. These doses are approximately 2.4, 1.5, and 0.8 times respectively the maximum recommended human dose of 30 mg/day on a mg/m<sup>2</sup> body surface area basis.

### Reproductive and Developmental toxicology

Amphetamine, in the enantiomer ratio present in mixed salts amphetamine extended-release capsules (*d*- to *l*- ratio of 3:1), did not adversely affect fertility or early embryonic development in the rat at doses of up to 20 mg/kg/day (approximately 5 times the maximum recommended human dose of 30 mg/day on a mg/m<sup>2</sup> body surface area basis). Fetal malformations and death have been reported in mice following parenteral administration of *d*-amphetamine doses of 50 mg/kg/day (approximately 6 times the maximum recommended human dose of 30 mg/day on a mg/m<sup>2</sup> basis) or greater to pregnant animals. Administration of these doses was also associated with severe maternal toxicity.

A number of studies in rodents indicate that prenatal or early postnatal exposure to amphetamine (*d*- or *d,l*-), at doses similar to those used clinically, can result in long-term neurochemical and behavioral alterations. Reported behavioral effects include learning and memory deficits, altered locomotor activity, and changes in sexual function.

### 17 Supporting Product Monographs

Adderall XR<sup>®</sup>, mixed salts amphetamine extended-release oral capsules, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, submission control no. 296552, Product Monograph, Takeda Canada Inc., Sep 12, 2025.

**PATIENT MEDICATION INFORMATION****READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE** **TARO-AMPHETAMINE XR****mixed salts amphetamine extended-release capsules**

This Patient Medication Information is written for the person who will be taking **TARO-AMPHETAMINE XR**. This may be you or a person you are caring for. Read this information carefully. Keep it as you may need to read it again.

This Patient Medication Information is a summary. It will not tell you everything about this medication. If you have more questions about this medication or want more information about **TARO-AMPHETAMINE XR**, talk to a healthcare professional.

**Serious Warnings and Precautions**

**The use of TARO-AMPHETAMINE XR can lead to drug dependence. TARO-AMPHETAMINE XR may also lead to the abuse and misuse of the drug.**

**Misusing TARO-AMPHETAMINE XR may cause serious heart problems and even sudden death.**

**What the TARO-AMPHETAMINE XR is used for:**

TARO-AMPHETAMINE XR is used to treat attention deficit hyperactivity disorder (ADHD) in children (6 to 12 years), adolescents (13 to 17 years) and adults. It may be a part of an overall treatment for ADHD. The healthcare professional may also recommend counselling or other therapy.

**How TARO-AMPHETAMINE work?**

TARO-AMPHETAMINE XR belongs to a group of medicines called central nervous system stimulants. TARO-AMPHETAMINE XR is believed to act on certain parts of the brain to help increase your attention and concentration. This includes the ability to follow directions, finish tasks, and reduce rash and uncontrolled behaviour. The TARO-AMPHETAMINE XR capsule also contains the medicinal ingredient, amphetamine, which is released immediately after taking the medicine and later during the day to keep improving the symptoms of ADHD throughout the day.

**The ingredients in TARO-AMPHETAMINE XR are:**

Medicinal ingredients: *d*-amphetamine Saccharate, Amphetamine Aspartate Monohydrate, *d*-amphetamine Sulfate and Amphetamine Sulfate

Nonmedicinal ingredients: black iron oxide, colloidal silicon dioxide, FD&C Blue #2 (5 mg, 10 mg, 15 mg,), FD&C Yellow #6, gelatin, hypromellose, methacrylic acid copolymer Type-B, methacrylic acid copolymer Type-C, polyethylene glycol, propylene glycol, shellac, sugar spheres, talc, titanium dioxide, and triethyl citrate. The 20 mg, 25 mg, and 30 mg capsules also contains yellow iron oxide and red iron oxide.

**TARO-AMPHETAMINE XR comes in the following dosage forms:**

Extended-release capsules: 5 mg, 10 mg, 15 mg, 20 mg, 25 mg and 30 mg

**Do not use TARO-AMPHETAMINE XR if:**

- you are allergic to amphetamines or any of the nonmedicinal ingredients in the formulation or its container.
- you are sensitive to, allergic to or had a reaction to other stimulant medicines.
- you have a condition that hardens the arteries.
- you have symptoms of heart disease.
- you have moderate to severe high blood pressure.
- you have a condition that causes anxious and distressful feelings.
- you have glaucoma, an eye disease.
- you have hyperthyroidism (a condition that causes the thyroid gland to make too much of a hormone).
- you have a history of drug abuse.
- you are taking or have taken medications from the group called monoamine oxidase inhibitors (MAOI) within the last 14 days.
- you are breastfeeding or plan to breastfeed. Mixed salts amphetamine passes into breast milk.
- you have a condition called pheochromocytoma (a rare tumour that usually grows in the adrenal glands, above your kidneys).

**To help avoid side effects and ensure proper use, talk to your healthcare professional before you take TARO-AMPHETAMINE XR. Talk about any health conditions or problems you may have, including if you:**

- have structural heart abnormalities, cardiomyopathy, serious heart rhythm (heartbeat) abnormalities or other serious heart problems.
- have a family history of sudden cardiac death or death related to heart problems.
- have mild high blood pressure.
- are involved in any physical exercises that are tiring on the body
- take other medicines for the treatment of ADHD
- have motion tics, verbal tics or Tourette’s syndrome (See **Serious side effects and what to do about them** below)
- have family with motion tics, verbal tics, or Tourette’s syndrome
- have a history of seizures (convulsions, epilepsy)
- have had an abnormal brain wave test when using an Electroencephalogram (EEG)
- have symptoms of:
  - Raynaud’s phenomenon (a condition that causes fingers and toes feeling numb, tingling and changing colour when cold)
  - Thromboangitis obliterans (that causes pain in hands and feet)
- have any kidney related problems as your healthcare professional may reduce the dose.
- have a history of drug abuse or alcoholism

**Other warnings you should know about:**

**Pregnancy:** Tell your healthcare professional if you are pregnant or plan to become pregnant. Taking TARO-AMPHETAMINE XR during pregnancy can cause harm to your unborn baby. If TARO-AMPHETAMINE XR is required during pregnancy, the risk to the unborn baby should be weighed against the benefits for the mother.

Your healthcare professional can discuss these issues with you.

**The following have been reported with use of medicines used to treat ADHD such as TARO-AMPHETAMINE XR:**

**Serotonin toxicity (also known as serotonin syndrome):**

TARO-AMPHETAMINE XR can cause serotonin toxicity, a rare but potentially life-threatening condition. It can cause serious changes in how your brain, muscles and digestive system work. You may develop serotonin toxicity if you take TARO-AMPHETAMINE XR with other serotonergic medicines, for example, certain antidepressants or migraine medications.

Serotonin toxicity symptoms include:

- fever, sweating, shivering, diarrhea, nausea, vomiting;
- muscle shakes, jerks, twitches or stiffness, overactive reflexes, loss of coordination;
- fast heartbeat, changes in blood pressure;
- confusion, agitation, restlessness, hallucinations, mood changes, unconsciousness, and coma.

**Heart-related problems:** The following heart related problems have been reported in people taking medications to treat ADHD, like TARO-AMPHETAMINE XR:

- sudden death in children, adolescents and adults who have heart problems or heart defects;
- stroke and heart attack in adults;
- increased blood pressure and heart rate.

Sudden death has been reported in children and adolescents treated with medicines for ADHD. Those children and adolescents had problems with the structure of their heart or had other serious heart problems. TARO-AMPHETAMINE XR generally should not be used in children, adolescents or adults who have any serious heart diseases or conditions, such as:

- high blood pressure,
- problems with the structure of their heart,
- diseases that impact the muscles of their heart,
- serious problems with their heartbeat.

Tell your healthcare professional if you have any heart problems, heart defects, high blood pressure, or a family history of these problems. Your healthcare professional may wish to check you for:

- heart problems before starting TARO-AMPHETAMINE XR.

- irregular blood pressure and heart rate during treatment with TARO-AMPHETAMINE XR.

**Call your healthcare professional right away if you have any signs of heart problems such as chest pain, shortness of breath, or fainting while taking TARO-AMPHETAMINE XR.**

#### **Mental (psychiatric) problems:**

- New or worse thoughts or feelings related to suicide. This can include thinking about or feeling like killing yourself and suicide attempts. This may happen at any time during treatment, especially at the start or during dose changes, and also after stopping the treatment of TARO-AMPHETAMINE XR. Should this happen to you, **talk to your healthcare professional immediately. Close observation by a healthcare professional is necessary in this situation.**
- New symptoms of mania. This can include unusual excited, over-active or unrestrained behavior.
- New or worse bipolar illness. This can appear as extreme mood swings (alternating from feelings of unusual excitement, over-active or un-inhibited to feelings of depression, sadness, worthlessness or hopelessness).
- New or worse aggressive behavior, anxiety, agitation or hostility.
- New symptoms of psychosis. This includes seeing or hearing voices that are not real, believing things that are not true, or are suspicious.

These problems are more likely to occur if you have any known or unknown mental disorders. Speak to the healthcare professional if you or family have or had:

- any mental disorders,
- bipolar illness,
- depression,
- a history of suicide.

#### **Drug abuse and dependence**

- TARO-AMPHETAMINE XR includes the medicinal ingredient, amphetamine. Amphetamines have the potential to cause drug abuse and misuse.
- Abuse of amphetamines can lead to dependence, tolerance, social disorders and possibly serious heart problems and death.
- Long term misuse of amphetamines may cause:
  - skin diseases;
  - sleeping problems;
  - personality changes;
  - anxious and distressful feelings;
  - rash, uncontrolled behaviour;
  - psychosis;
  - schizophrenia.
- Healthcare professional supervision is needed when you stop taking TARO-AMPHETAMINE XR. Suddenly ending treatment when taking higher doses of TARO-AMPHETAMINE XR for a long period of time can cause:
  - extreme fatigue,
  - depression,
  - changes in sleep patterns.
- TARO-AMPHETAMINE XR should only be given under close medical supervision to patients whose condition has been properly diagnosed.

#### **Growth in children**

Stimulants are possibly believed to temporarily slow growth in children. The healthcare professional will be monitoring the child's height and weight while they are taking TARO-AMPHETAMINE. If the child is not growing or gaining weight as the healthcare professional expects, the healthcare professional may stop TARO-AMPHETAMINE XR treatment.

**Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.**

#### **Serious drug interactions**

##### **Serious drug interactions with TARO-AMPHETAMINE XR include:**

- any monoamine oxidase inhibitors (MAOIs) such as phenelzine, tranylcypromine, or moclobemide as it may have serious side effects. Do not take TARO-AMPHETAMINE XR if you are taking or have recently taken (in the last 14 days) any MAOIs.

**The following may also interact with TARO-AMPHETAMINE XR:**

- medicines used to treat depression including St. John's Wort, selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs).
- medicines used to treat migraines called triptans.
- medicines that make urine or digestive contents more acidic (e.g., guanethidine, reserpine, ascorbic acid, ammonium chloride, sodium acid phosphate).
- medicines that make urine more alkaline (e.g., acetazolamide, thiazides).
- medicines used to reduce or increase blood pressure.
- cold and allergy medicines.
- antipsychotic medicines (e.g., chlorpromazine, haloperidol).
- Lithium.
- methamphetamine therapy.
- opioid pain medicines (e.g., meperidine, tramadol).
- seizure medicines (e.g., ethosuximide, phenobarbital, phenytoin).
- certain radioactive agents (used for diagnostic tests). This can cause false-positive test results and your healthcare professional may ask you to stop taking ADDERALL XR for a short period before the diagnostic test.

While on TARO-AMPHETAMINE XR, do not start taking a new medicine or herbal remedy before checking with the healthcare professional.

**You should not take the following medications with TARO-AMPHETAMINE XR:**

- medicines that make digestive contents more alkaline (e.g., sodium bicarbonate, antacids).
- proton pump inhibitors, commonly known as PPIs (e.g., omeprazole).

**How to take TARO-AMPHETAMINE XR:**

- Take exactly as the healthcare professional tells you to take it. **Do NOT** take more of it than prescribed.
  - Take it only by mouth, once-a-day early in the morning.
  - Avoid taking TARO-AMPHETAMINE XR in the afternoon as it can cause insomnia.
  - You may take TARO-AMPHETAMINE XR by:
    - swallowing capsules whole; or
    - opening the capsule and sprinkling all the beads on applesauce. Use immediately and do not store for later use if this method is used.
  - **Do not crush or chew the capsule or the beads before swallowing.**
- Can be taken with or without meals.
- Capsules may be swallowed whole with water

**Usual dose:**

**Children (6 to 12 years of age):** The usual starting dose is 10 mg once a day in the morning. In some cases, the starting dose can be 5 mg once a day. Do not take more than 30 mg once a day.

**Adolescents (13 to 17 years of age) and Adults (18 years of age and over):** The usual starting dose is 10 mg once a day in the morning. The dose may be adjusted up to the usual maximum dose of 20 mg once a day. Do not take more than 30 mg once a day.

Your healthcare professional may:

- stop your treatment of TARO-AMPHETAMINE XR to assess the return of symptoms,
- change the dose depending on how you respond to TARO-AMPHETAMINE XR.

**Overdose:**

If you think you, or a person you are caring for, have taken too much TARO-AMPHETAMINE XR, contact a healthcare professional, hospital emergency department, regional poison control centre, or Health Canada's toll-free number, 1-844 POISON-X (1-844-764-7669) immediately, even if there are no signs or symptoms.

**Missed dose:**

If you forget to take your dose in the morning, wait until the next morning and carry on with the next dose at the usual time. Do not double dose.

**Possible side effects from using TARO-AMPHETAMINE XR:**

These are not all the possible side effects you may have when taking TARO-AMPHETAMINE XR. If you experience any side effects not listed here, tell your healthcare professional.

Side effects of TARO-AMPHETAMINE XR may include:

- behavioural changes (e.g., anxiety, irritability, mood swings, and nervousness);
  - chills;
  - decrease or loss of appetite;
  - difficulty falling asleep;
- digestive problems (e.g., constipation, diarrhea, indigestion, nausea, and vomiting);
- dizziness;
  - drowsiness;
  - dry mouth and thirst;
  - fever;
  - grinding of teeth;
  - headache;
  - neck pain;
  - reduced sexual drive;
  - sensitive to light;
  - stomach ache;
  - sweating;
  - unpleasant taste;
  - weight loss.

**Serious side effects and what to do about them**

Frequency/ Side Effect/Symptom	Talk to your healthcare professional		Stop taking this drug and get immediate medical help
	Only if severe	In all cases	
<b>Common</b>			
<b>Allergic reaction:</b> rash, hives, swelling of the face, lips, tongue or throat, difficulty swallowing or breathing			✓
<b>Cardiomyopathy</b> (signs of heart muscle disease): breathlessness or swelling of the legs		✓	
<b>Depression:</b> feeling sad, loss of interest in usual activities, hopelessness, insomnia or sleeping too much		✓	
<b>Dyspnea:</b> shortness of breath			✓
<b>Heart palpitations or fast heart beat:</b> skipping beats, beating too fast, pounding, fluttering rapidly		✓	
<b>New tics:</b> hard to control motion tics (repeat twitching of any parts of the body) or verbal tics (repeating of sounds or words)		✓	
<b>Urinary tract infection (infection in urinary system including kidneys, ureters, bladder and urethra):</b> pain or burning sensation while urinating, frequent urination, blood in urine, pain in the pelvis, strong smelling urine, cloudy urine		✓	
<b>Uncommon</b> <b>Aggressive behavior, anger or hostility</b>		✓	
<b>High blood pressure:</b> headaches, dizziness, lightheadedness, ringing in the ears, fainting		✓	
<b>Trouble with vision:</b> eyesight changes or blurred vision		✓	

Frequency/ Side Effect/Symptom	Talk to your healthcare professional		Stop taking this drug and get immediate medical help
	Only if severe	In all cases	
<b>Unknown</b>			
<b>Condition Resembling Raynaud's Phenomenon:</b> discoloration of the hands and feet, pain, sensations of cold and/or numbness		✓	
<b>Epistaxis or contusion:</b> unexplained nosebleeds or bruising	✓		
<b>Heart attack:</b> severe, crushing chest pain that can radiate into the arm and/or jaw, palpitations, shortness of breath, nausea, vomiting, sweating			✓
<b>Intestinal ischemia (blood flow to the intestines decreases due to a narrowed or blocked blood vessel):</b> sudden or worsening abdominal pain (usually severe), urgent need to have a bowel movement, frequent, forceful bowel movements, nausea, vomiting, diarrhea, blood in the stool, confusion in older adults			✓
<b>New psychotic or manic symptoms: paranoia, delusions</b> - <b>Hallucinations:</b> seeing, feeling or hearing things that are not real - <b>Mania:</b> feeling unusually excited, over-active, or uninhibited, picking of skin		✓	
<b>Seizures (fits):</b> loss of consciousness with uncontrollable shaking			✓
<b>Serious skin conditions (Steven's Johnson Syndrome, Toxic Epidermal Necrolysis):</b> swelling of the skin or serious skin rash seen as severe blisters of the skin and mucous membranes			✓
<b>Serotonin toxicity (also known as serotonin syndrome):</b> a reaction which may cause feelings of agitation or restlessness, flushing, muscle twitching, involuntary eye movements, heavy sweating, high body temperature (>38 °C), or rigid muscles			✓
<b>Stroke:</b> weakness, trouble speaking, vision problems, headache, dizziness			✓
<b>Suicidal behavior:</b> thoughts or actions about hurting or killing yourself			✓

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

#### Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

Visiting the Web page on Adverse Reaction Reporting ([canada.ca/drug-device-reporting](http://canada.ca/drug-device-reporting)) for information on how to report online, by mail or by fax; or

Calling toll-free at 1-866-234-2345.

*NOTE: Contact your healthcare professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.*

#### Storage:

Store at 20°-25°C; excursions permitted 15°-30°C; dispense in tight, light-resistant container.

Keep out of reach and sight of children.

**If you want more information about TARO-AMPHETAMINE XR:**

- Talk to your healthcare professional.
- Find the full Product Monograph that is prepared for healthcare professionals and includes the Patient Medication Information by visiting the Health Canada Drug Product Database website (<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>); or by calling 1-866-840-1340.

This leaflet was prepared by:

Sun Pharma Canada Inc.,  
Brampton, ON  
L6T 1C1

Last revised: FEB 09, 2026

All trademarks are property of their respective owners.